多发性硬化症认知障碍的非药理疗法:综述
Michela Bossa1, Nicola Manocchio2, Ornella Argento1
1Behavioral Neuropsychology Laboratory, I.R.C.C.S. "Santa Lucia" Foundation, 00179 Rome, Italy.
NeuroSci
|November 1, 2024
概括
非药物认知康复 (CR) 有效地减少了多发性硬化症 (MS) 患者的认知障碍 (CI). 计算机化CR具有吸引力,而像虚拟现实这样的创新方法显示出未来的希望.
科学领域:
- 神经学 神经学
- 康复医学 康复医学 康复医学
- 认知科学 认知科学
背景情况:
- 认知障碍 (CI) 是多发性硬化症 (MS) 的普遍和衰弱症状.
- CI影响所有疾病阶段,显著影响患者的生活质量.
- 越来越多地探索非药理干预措施来管理MS相关的CI.
研究的目的:
- 审查当前关于管理MS患者CI的非药理学方法的证据.
- 提供全球治疗方法的概述,从传统到新的技术.
- 评估各种认知康复 (CR) 策略的有效性.
主要方法:
- 在PubMed上系统地搜索文学,寻找在过去五年内发表的英语文章,重点是人类研究.
- 选标题,摘要和全文,以确定符合条件的研究.
- 37个选定的文章被分类为现场干预,远程康复和各种类别.
主要成果:
- 尽管方法异质,但非药理学方法在改善MS相关CI方面表现出有效性.
- 认知康复 (CR) 是有效和成熟的,计算机化CR以其吸引力而闻名.
- 对于CR组的数据有限,VR,神经反和生活方式变化等创新方法需要进一步调查.
结论:
- 非药理学策略,特别是CR,为解决多发性硬化症认知障碍提供了可行和有效的手段.
- 计算机化CR为患者提供了一个有吸引力的选择.
- 未来的研究应该专注于新的干预措施和基于组的CR,以扩大治疗选择.
相关概念视频
Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...


